Linagliptin–-A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
Incretin based therapies have been introduced into the treatment options of type 2 diabetes a few years ago. Among them, the orally active DPP-4 inhibitors have established themselves as insulinotropic agents. Their advantage is the glucose-dependent insulinotropic action without an intrinsic risk f...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2012-01-01
|
| coleção: | Clinical Medicine Insights: Endocrinology and Diabetes |
| Acesso em linha: | https://doi.org/10.4137/CMED.S7274 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|